Capping Lawyers’ Tobacco Fees

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

WASHINGTON--One of Shakespeare’s characters wanted to "kill all the lawyers." Rep. Scott McInnis (R-Colo) just wants to cap their legal fees, at least in any national tobacco agreement. In introducing a bill to limit any legal fees from a settlement to $150 an hour plus expenses, Rep. McInnis noted that some states have entered into contracts with private attorneys that called for payments of up to 25% of funds collected from tobacco cases.

WASHINGTON--One of Shakespeare’s characters wanted to "kill all the lawyers." Rep. Scott McInnis (R-Colo) just wants to cap their legal fees, at least in any national tobacco agreement. In introducing a bill to limit any legal fees from a settlement to $150 an hour plus expenses, Rep. McInnis noted that some states have entered into contracts with private attorneys that called for payments of up to 25% of funds collected from tobacco cases.

"I hope this legislation will serve to initiate the debate regarding how the money from a tobacco settlement deal is to be allocated," he said. "I believe that the funds would best be used to prevent underage smoking, not to line the pockets of a few trial attorneys."

For example, lawyers in the recent multibillion dollar Texas settlement stand to collect $2.2 billion under their contract with the state.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content